What are the recommended dosages of dapagliflozin (Farxiga) and glipizide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Dosages for Farxiga (Dapagliflozin) and Glipizide

For dapagliflozin (Farxiga): start with 5 mg once daily for glycemic control, which can be increased to 10 mg once daily if additional glucose lowering is needed; for cardiovascular and kidney protection indications, use 10 mg once daily. 1

For glipizide: initiate conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia, particularly in patients with reduced kidney function. 2

Dapagliflozin (Farxiga) Dosing

For Glycemic Control in Type 2 Diabetes

  • Starting dose: 5 mg orally once daily 1
  • Maximum dose: 10 mg orally once daily if additional glycemic control is needed 1
  • Timing: Can be taken at any time of day, with or without food

For Cardiovascular and Kidney Protection

  • Standard dose: 10 mg orally once daily for all non-glycemic indications 1
  • This includes:
    • Reducing risk of sustained eGFR decline, ESKD, CV death, and heart failure hospitalization in chronic kidney disease
    • Reducing risk of CV death, heart failure hospitalization, and urgent heart failure visits in heart failure patients
    • Reducing risk of heart failure hospitalization in T2DM patients with established CVD

Kidney Function Adjustments

For glycemic control:

  • eGFR ≥45 mL/min/1.73 m²: No dose adjustment needed 3, 2, 1
  • eGFR <45 mL/min/1.73 m²: Not recommended for glycemic control (ineffective due to mechanism of action) 3, 2, 1

For cardiovascular/kidney protection indications:

  • eGFR ≥25 mL/min/1.73 m²: Use standard 10 mg dose 2, 1
  • eGFR <25 mL/min/1.73 m²: Do not initiate, but may continue 10 mg if already on therapy 2, 1
  • eGFR <20 mL/min/1.73 m²: Initiation not recommended, but continuation acceptable for kidney/CV benefit until dialysis 2

Important Considerations

  • Withhold for at least 3 days before major surgery or prolonged fasting to reduce ketoacidosis risk 1
  • The glucose-lowering effect diminishes as eGFR declines, but cardiovascular and kidney benefits persist 2

Glipizide Dosing

Standard Dosing

  • Initial dose: 2.5 mg once daily (conservative initiation) 2
  • Titration: Increase slowly based on glycemic response and tolerability
  • Timing: Typically taken before meals

Kidney Function Adjustments

  • All stages of CKD (eGFR 30-44 mL/min/1.73 m²): Initiate conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia 2
  • Severe kidney impairment: Use with extreme caution due to increased hypoglycemia risk
  • Note: Glyburide (not glipizide) is specifically not recommended in kidney disease 2

Critical Clinical Pitfalls

For Dapagliflozin

  • Volume depletion risk: Assess volume status before initiation; consider reducing diuretic doses in at-risk patients 2
  • Genital mycotic infections: Occur in ~6% of patients (vs. 1% placebo); counsel on hygiene 2
  • Ketoacidosis risk: Rare but serious; maintain at least low-dose insulin in insulin-requiring patients; implement sick-day protocols 2
  • Reversible eGFR decline: Expected initial drop of 3-5 mL/min/1.73 m² is hemodynamic and not a reason to discontinue 2

For Glipizide

  • Hypoglycemia: Major concern, especially in elderly and those with kidney disease; occurs in ~40-46% of patients in comparative trials 4, 5
  • Weight gain: Average 1.2 kg gain vs. 3.2 kg loss with dapagliflozin 5
  • Poor glycemic durability: Coefficient of failure 0.59%/year vs. 0.13%/year with dapagliflozin 4

Combination Considerations

When adding dapagliflozin to patients already on glipizide, reduce or discontinue the sulfonylurea to prevent hypoglycemia, as dapagliflozin provides glucose lowering without insulin stimulation 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.